Inclisiran: First Approval
Author:
Top Cited Papers
Open Access
- 23 February 2021
- journal article
- research article
- Published by Springer Nature in Drugs
- Vol. 81 (3) , 389-395
Abstract
Inclisiran (Leqvio®; Novartis) is a first-in-class, cholesterol-lowering small interfering RNA (siRNA) conjugated to triantennary N-acetylgalactosamine carbohydrates (GalNAc). Inclisiran received its first approval in December 2020 in the EU for use in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet. It is intended for use in combination with a statin or a statin with other lipid-lowering therapies in patients unable to reach low-density lipoprotein cholesterol goals with the maximum tolerated statin dose. In patients who are statin-intolerant or for whom a statin is contraindicated, inclisiran can be used alone or in combination with other lipid-lowering therapies. Inclisiran is administered as a twice-yearly subcutaneous injection. This article summarizes the milestones in the development of inclisiran leading to this first approval for primary hypercholesterolaemia or mixed dyslipidaemia.Keywords
This publication has 15 references indexed in Scilit:
- Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL CholesterolNew England Journal of Medicine, 2020
- EVALUATION OF LDL-C REDUCTIONS BY SIRNA TREATMENT WITH INCLISIRAN IN PATIENTS WITH DIABETES MELLITUS, METABOLIC SYNDROME OR NEITHERJACC, 2020
- INCLISIRAN AND CARDIOVASCULAR OUTCOMES: ANALYSES FROM ORION-11JACC, 2020
- Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 StudiesMayo Clinic Proceedings, 2020
- Small Interfering RNA Therapeutic Inclisiran: A New Approach to Targeting PCSK9BioDrugs, 2019
- Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol LevelsJAMA Cardiology, 2019
- Comparative Effectiveness of Inclisiran 100, 300, and 500 mg in a Population with Hyperlipidemia: A Network Meta-Analysis of Randomized Controlled TrialsAmerican Journal of Cardiovascular Drugs, 2018
- Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL CholesterolNew England Journal of Medicine, 2017
- A Highly Durable RNAi Therapeutic Inhibitor of PCSK9New England Journal of Medicine, 2017
- Multivalent N-Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene SilencingJournal of the American Chemical Society, 2014